Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P08887

UPID:
IL6RA_HUMAN

ALTERNATIVE NAMES:
IL-6R 1; Membrane glycoprotein 80

ALTERNATIVE UPACC:
P08887; A8KAE8; B2R6V4; Q16202; Q53EQ7; Q5FWG2; Q5VZ23

BACKGROUND:
The Interleukin-6 receptor subunit alpha, known alternatively as IL-6R 1 or Membrane glycoprotein 80, is integral to the immune system's response to inflammation and infection. It engages in various signaling pathways, including 'classic', 'trans', and 'cluster signaling', to regulate immune activities and blood cell formation. The receptor's soluble form, sIL6R, is pivotal in pro-inflammatory activities and plays a role in vascular endothelial growth factor (VEGF) production and liver regeneration.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Interleukin-6 receptor subunit alpha could open doors to potential therapeutic strategies for treating Hyper-IgE recurrent infection syndrome 5 and other chronic inflammatory conditions. Its critical role in immune response modulation and tissue regeneration makes it a promising target for drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.